Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCED-3: Intravesical TARA-002 vs Intravesical Chemotherapy in BCG-naive High-Grade NMIBC
jRCT2041260091Phase 3Not yet recruiting
- Sponsor
- Protara Therapeutics
- Start
- Jul 2026
- Modality
- Cell Therapies
01
Overview
Phase 3, randomised trial of TARA-002 in bladder cancer (2 arms), sponsored by Protara Therapeutics. Primary endpoint: Incidence of high-grade complete response at Month 6. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
TARA-002
03
Conditions
bladder cancer
Beyond the preview
Go deeper on jRCT2041260091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260091.